Patents by Inventor Claus Bornæs

Claus Bornæs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS
    Publication number: 20220133707
    Abstract: The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders.
    Type: Application
    Filed: January 12, 2022
    Publication date: May 5, 2022
    Inventors: Anders Mørkeberg HINSBY, Thomas Kirkegaard JENSEN, Catherine Kolster FOG-TONNESEN, Nikolaj Havnsøe Torp PETERSEN, Claus BORNÆS
  • Arimoclomol for treating glucocerebrosidase associated disorders
    Patent number: 11253505
    Abstract: The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: February 22, 2022
    Assignee: Orphazyme A/S
    Inventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Catherine Kolster Fog-Tonnesen, Nikolaj Havnsøe Torp Petersen, Claus Bornæs
  • ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS
    Publication number: 20200289497
    Abstract: The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders.
    Type: Application
    Filed: May 20, 2020
    Publication date: September 17, 2020
    Inventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Catherine Kolster Fog-Tonnesen, Nikolaj Havnsøe Torp Petersen, Claus Bornæs
  • ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS
    Publication number: 20190111041
    Abstract: The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximioyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders.
    Type: Application
    Filed: April 28, 2017
    Publication date: April 18, 2019
    Inventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Catherine Kolster Fog-Tonnesen, Nikolaj Havnsøe Torp Petersen, Claus Bornæs
  • Factor VII or Factor VIIa Gla domain variants
    Patent number: 8987202
    Abstract: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to the human Factor VII or human Factor VIIa sequence shown in SEQ ID NO:1, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: March 24, 2015
    Assignee: Bayer Healthcare LLC
    Inventors: Jesper Mortensen Haaning, Kim Vilbour Andersen, Claus Bornaes
  • Factor VII or VIIa - Like Molecules
    Publication number: 20120171765
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Application
    Filed: November 18, 2011
    Publication date: July 5, 2012
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Factor VII or VIIA-like molecules
    Patent number: 8084591
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: December 27, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Factor V11 or factor V11A GLA domain variants
    Patent number: 7807638
    Abstract: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34 or having an amino acid substitution in position 36 of the amino acid sequence shown in SEQ ID NO:1; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: October 5, 2010
    Assignee: Bayer Healthcare LLC
    Inventors: Jesper Mortensen Haaning, Kim Vilbour Andersen, Claus Bornaes
  • Factor VII or VIIa—like molecules
    Patent number: 7754682
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: July 13, 2010
    Assignee: Bayer Healthcare LLC
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Factor VII or VIIa-like molecules
    Patent number: 7517974
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Grant
    Filed: March 30, 2006
    Date of Patent: April 14, 2009
    Assignee: Bayer Healthcare LLC
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Factor VII or VIIA-like molecules
    Patent number: 7511024
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: March 31, 2009
    Assignee: Bayer HealthCare LLC
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Interferon Beta-Like Molecules
    Publication number: 20090030183
    Abstract: The invention relates to a conjugate exhibiting interferon ? (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.
    Type: Application
    Filed: September 8, 2008
    Publication date: January 29, 2009
    Inventors: Poul Baad Rasmussen, Joern Drustrup, Grethe Rasmussen, Anders Hjelholt Pedersen, Hans Thalsgard Schambye, Kim Vilbour Andersen, Claus Bornaes
  • Factor VII or VIIa - Like Molecules
    Publication number: 20090023635
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Application
    Filed: October 30, 2007
    Publication date: January 22, 2009
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Factor VII or VIIa-like molecules
    Patent number: 7442524
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: October 28, 2008
    Assignee: Maxygen Holdings Ltd.
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Interferon beta-like molecules
    Patent number: 7431921
    Abstract: The invention relates to a conjugate exhibiting interferon ? (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: October 7, 2008
    Assignee: Maxygen ApS
    Inventors: Poul Baad Rasmussen, Grethe Rasmussen, Kim Vilbour Andersen, Claus Bornaes
  • Factor VII or VIIa - like molecules
    Patent number: 7427592
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: September 23, 2008
    Assignee: Maxygen Holdings Ltd.
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Factor VII or VIIa-like molecules
    Patent number: 7414022
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: August 19, 2008
    Assignee: Maxygen Holdings Ltd.
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Factor VII or VIIa-like molecules
    Patent number: 7371543
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: May 13, 2008
    Assignee: Maxygen Holdings Ltd.
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Interferon-? variants and conjugates
    Patent number: 7338788
    Abstract: The present invention provides new interferon ? conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: March 4, 2008
    Assignee: Maxygen ApS
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes, Poul Baad Rasmussen
  • Factor VII or VIIa - Like Molecules
    Publication number: 20070243588
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Application
    Filed: April 12, 2006
    Publication date: October 18, 2007
    Inventors: Anders Pedersen, Kim Andersen, Claus Bornaes